EU Approves Johnson & Johnson's TREMFYA for Paediatric Plaque Psoriasis
I'm PortAI, I can summarize articles.
The European Commission has approved Johnson & Johnson's TREMFYA® (guselkumab) for treating moderate to severe plaque psoriasis in children and adolescents aged 6 years and older. This is the first paediatric indication for an IL-23 inhibitor, supported by data from the Phase 3 PROTOSTAR study showing higher skin clearance with guselkumab compared to placebo.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments